Alector (ALEC) Competitors

Bicycle Therapeutics (NASDAQ:BCYC) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, community ranking, earnings, profitability and analyst recommendations.

Which has higher earnings and valuation, BCYC or ALEC?

Alector has higher revenue and earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$25.72M	23.26	-$180.66M	-$3.14	-2.75
Alector	$88.34M	1.80	-$130.39M	-$1.26	-1.26

Which has more volatility & risk, BCYC or ALEC?

Bicycle Therapeutics has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Alector has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.

Do analysts recommend BCYC or ALEC?

Bicycle Therapeutics presently has a consensus target price of $25.00, suggesting a potential upside of 189.35%. Alector has a consensus target price of $4.00, suggesting a potential upside of 151.57%. Given Bicycle Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Bicycle Therapeutics is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70
Alector	2 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.14

Does the MarketBeat Community favor BCYC or ALEC?

Alector received 11 more outperform votes than Bicycle Therapeutics when rated by MarketBeat users. However, 70.53% of users gave Bicycle Therapeutics an outperform vote while only 61.09% of users gave Alector an outperform vote.

Company	Underperform	Outperform
Bicycle Therapeutics	Outperform Votes 146 70.53%	Underperform Votes 61 29.47%
Alector	Outperform Votes 157 61.09%	Underperform Votes 100 38.91%

Do institutionals and insiders believe in BCYC or ALEC?

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 22.9% of Bicycle Therapeutics shares are owned by insiders. Comparatively, 9.1% of Alector shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the media prefer BCYC or ALEC?

In the previous week, Bicycle Therapeutics had 2 more articles in the media than Alector. MarketBeat recorded 6 mentions for Bicycle Therapeutics and 4 mentions for Alector. Alector's average media sentiment score of 0.48 beat Bicycle Therapeutics' score of 0.04 indicating that Alector is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alector	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is BCYC or ALEC more profitable?

Alector has a net margin of -257.54% compared to Bicycle Therapeutics' net margin of -450.64%. Bicycle Therapeutics' return on equity of -27.35% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-450.64%	-27.35%	-20.81%
Alector	-257.54%	-108.77%	-27.03%

Summary

Bicycle Therapeutics beats Alector on 11 of the 18 factors compared between the two stocks.